Search

Your search keyword '"Faivre, Jean-Christophe"' showing total 35 results
Start Over Author "Faivre, Jean-Christophe"
35 results on '"Faivre, Jean-Christophe"'

1. Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas

Author

Meyer, Céline, Huger, Sandrine, Bruand, Marie, Leroy, Thomas, Palisson, Jérémy, Rétif, Paul, Sarrade, Thomas, Barateau, Anais, Renard, Sophie, Jolnerovski, Maria, Demogeot, Nicolas, Marcel, Johann, Martz, Nicolas, Stefani, Anaïs, Sellami, Selima, Jacques, Juliette, Agnoux, Emma, Gehin, William, Trampetti, Ida, Margulies, Agathe, Golfier, Constance, Khattabi, Yassir, Cravéreau, Olivier, Renan, Alizée, Py, Jean-François, and Faivre, Jean-Christophe

Published
2024
Full Text
View/download PDF

6. Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma—a French DELPHI Consensus Initiative

Author

Basse, Clémence, Khalifa, Jonathan, Thillays, François, Le Pechoux, Cécile, Maury, Jean-Michel, Bonte, Pierre-Emmanuel, Coutte, Alexandre, Pourel, Nicolas, Bourbonne, Vincent, Pradier, Olivier, Belliere, Aurélie, Le Tinier, Florence, Deberne, Mélanie, Tanguy, Ronan, Denis, Fabrice, Padovani, Laetitia, Zaccariotto, Audrey, Molina, Thierry, Chalabreysse, Lara, Brioude, Geoffrey, Delatour, Bertrand, Faivre, Jean-Christophe, Cao, Kim, Giraud, Philippe, Riet, François-Georges, Thureau, Sébastien, Antoni, Delphine, Massabeau, Carole, Keller, Audrey, Bonnet, Emilie, Lerouge, Delphine, Martin, Etienne, Girard, Nicolas, and Botticella, Angela

Published
2024
Full Text
View/download PDF

7. Survival Without Quality of Life Deterioration in the GORTEC 2014-04 “OMET” Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR

Author

Thariat, Juliette, Bosset, Mathieu, Pointreau, Yoann, Racadot, Severine, Faivre, Jean-Christophe, Castelli, Joel, Guihard, Sebastien, Huguet, Florence, Chapet, Sophie, Tao, Yungan, Borel, Christian, Fayette, Jerome, Pechery, Adeline, Bourhis, Jean, Sun, Xu-Shan, Falcoz, Antoine, Vernerey, Dewi, Rambeau, Audrey, and Ferrand, François-Régis

Published
2024
Full Text
View/download PDF

8. Acute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort

Author

Bruand, Marie, Salleron, Julia, Guihard, Sébastien, Crety, Charles Marchand, Liem, Xavier, Pasquier, David, Lamrani-Ghaouti, Assia, Charra-Brunaud, Claire, Peiffert, Didier, Clavier, Jean-Baptiste, Desandes, Emmanuel, and Faivre, Jean-Christophe

Published
2022
Full Text
View/download PDF

9. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

Author

Thureau, Sébastien, Marchesi, Vincent, Vieillard, Marie-Hélène, Perrier, Lionel, Lisbona, Albert, Leheurteur, Marianne, Tredaniel, Jean, Culine, Stéphane, Dubray, Bernard, Bonnet, Naïma, Asselain, Bernard, Salleron, Julia, and Faivre, Jean-Christophe

Published
2021
Full Text
View/download PDF

10. Unilateral or bilateral irradiation in cervical lymph node metastases of unknown primary? A retrospective cohort study

Author

Pflumio, Carole, Troussier, Idriss, Sun, Xu Shan, Salleron, Julia, Petit, Claire, Caubet, Matthieu, Beddok, Arnaud, Calugaru, Valentin, Servagi-Vernat, Stéphanie, Castelli, Joël, Miroir, Jessica, Krengli, Marco, Giraud, Paul, Romano, Edouard, Khalifa, Jonathan, Doré, Mélanie, Blanchard, Nicolas, Coutte, Alexandre, Dupin, Charles, Sumodhee, Shakeel, Pointreau, Yoann, Patel, Samir, Rehailia-Blanchard, Amel, Catteau, Ludivine, Bensadoun, René-Jean, Tao, Yungan, Roth, Vincent, Geoffrois, Lionnel, Faivre, Jean-Christophe, and Thariat, Juliette

Published
2019
Full Text
View/download PDF

18. Prognostic factors of local control and progression-free survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy

Author

Faivre, Jean-Christophe, primary, Jung, Paul, additional, Salleron, Julia, additional, Baumard, Florian, additional, Courrech, Florent, additional, Marchal, Frédéric, additional, Peiffert, Didier, additional, Renard, Sophie, additional, and Charra-Brunaud, Claire, additional

Published
2023
Full Text
View/download PDF

20. Prognostic factors of local control and progressionfree survival in AJCC stages T1 and T2 cervical cancer patients treated with adjuvant brachytherapy after chemoradiotherapy.

Author

Faivre, Jean-Christophe, Jung, Paul, Salleron, Julia, Baumard, Florian, Courrech, Florent, Marchal, Frédéric, Peiffert, Didier, Renard, Sophie, and Charra-Brunaud, Claire

Subjects
*PROGNOSIS, *CERVICAL cancer, *RADIOISOTOPE brachytherapy, *CANCER patients, *HIGH dose rate brachytherapy, *CHEMORADIOTHERAPY, *INTERSTITIAL brachytherapy
Abstract

Purpose: We assessed prognostic factors of local control and progression-free survival (PFS) of patients treated for AJCC stages T1 and T2 cervical cancer using utero-vaginal brachytherapy after chemoradiotherapy. Material and methods: This retrospective single-institution analysis included patients who underwent brachytherapy after radiochemotherapy between 2005 and 2015 at the Institut de Cancérologie de Lorraine. Adjuvant hysterectomy was optional. A multivariate analysis of prognostic factors was carried out. Results: Of 218 patients, 81 (37.2%) were AJCC stage T1, and 137 (62.8%) were AJCC stage T2. 167 (76.6%) patients had squamous cell carcinoma, 97 (44.5%) patients had pelvic nodal disease, and 30 (13.8%) patients had para-aortic nodal disease. One hundred eighty-four patients (84.4%) underwent concomitant chemotherapy, while adjuvant surgery was performed in 91 patients (41.9%) and 42 (46.2%) patients had pathological complete response. Median follow-up was 4.2 years, and local control was reported in 87.8% (95% CI: 83.0-91.8) and 87.2% (95% CI: 82.3-91.3) of patients at 2 and 5 years, respectively. In multivariate analysis, T stage (hazard ratio [HR] = 3.65, 95% CI: 1.27-10.46, p = 0.016) was associated with local control. PFS was reported in 67.6% (95% CI: 60.9-73.4) and 57.4% (95% CI: 49.3-64.2) of patients at 2 and 5 years, respectively. In multivariate analysis, para-aortic nodal disease (HR = 2.03, 95% CI: 1.16-3.54, p = 0.012), pathological complete response (HR = 0.33, 95% CI: 0.15-0.73, p = 0.006), and intermediate-risk clinical tumor volume of > 60 cc (HR = 1.90, 95% CI: 1.22-2.98, p = 0.005) were associated with PFS. Conclusions: Lower dose brachytherapy may benefit AJCC stages T1 and T2 tumors, whereas higher doses are required for larger tumors and para-aortic nodal disease involvement, respectively. Pathological complete response should be associated with better local control and not surgery. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

21. Correction: Artificial intelligence contouring in radiotherapy for organs-at-risk and lymph node areas

Author

Meyer, Céline, Huger, Sandrine, Bruand, Marie, Leroy, Thomas, Palisson, Jérémy, Rétif, Paul, Sarrade, Thomas, Barateau, Anais, Renard, Sophie, Jolnerovski, Maria, Demogeot, Nicolas, Marcel, Johann, Martz, Nicolas, Stefani, Anaïs, Sellami, Selima, Jacques, Juliette, Agnoux, Emma, Gehin, William, Trampetti, Ida, Margulies, Agathe, Golfier, Constance, Khattabi, Yassir, Cravéreau, Olivier, Renan, Alizée, Py, Jean-François, and Faivre, Jean-Christophe

Published
2025
Full Text
View/download PDF

22. MéMoPratic’ VDHA: guide de prescription pour les voies digestives hautes altérées

Author

Faivre, Jean-Christophe, Mecellem, Hinda, Albertini, Llaëtitia, Belle, Arthur, Henry, Aline, Rousselot, Hhubert, Cretineau, Nathalie, Montaut, Thierry, Chone, Laurence, Cabessut, Sophie, Bevilacqua, Sybille, Henneton, Catherine, Scotté, Florian, Launay-Vacher, Vincent, Chenot, Émile-Dorian, Desandes, Emmanuel, Toussaint, Sophie, Peiffert, Didier, and Krakowski, Ivan

Published
2011
Full Text
View/download PDF

24. Impact of Neck Dissection in Head and Neck Squamous Cell Carcinomas of Unknown Primary

Author

Abu-Shama, Yazan, primary, Salleron, Julia, additional, Carsuzaa, Florent, additional, Sun, Xu-Shan, additional, Pflumio, Carole, additional, Troussier, Idriss, additional, Petit, Claire, additional, Caubet, Matthieu, additional, Beddok, Arnaud, additional, Calugaru, Valentin, additional, Servagi-Vernat, Stephanie, additional, Castelli, Joël, additional, Miroir, Jessica, additional, Krengli, Marco, additional, Giraud, Paul, additional, Romano, Edouard, additional, Khalifa, Jonathan, additional, Doré, Mélanie, additional, Blanchard, Nicolas, additional, Coutte, Alexandre, additional, Dupin, Charles, additional, Sumodhee, Shakeel, additional, Tao, Yungan, additional, Roth, Vincent, additional, Geoffrois, Lionel, additional, Toussaint, Bruno, additional, Nguyen, Duc Trung, additional, Faivre, Jean-Christophe, additional, and Thariat, Juliette, additional

Published
2021
Full Text
View/download PDF

26. Adapting palliative radiation therapy for bone metastases during the Covid-19 pandemic: GEMO position paper.

Author

UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service de radiologie, Thureau, Sébastien, Faivre, Jean Christophe, Assaker, Richard, Biver, Emmanuel, Confavreux, Cyrille B, Debiais, Françoise, Duterque-Coquillaud, Martine, Giammarile, Francesco, Heymann, Dominique, Lecouvet, Frédéric, Morardet, Laetitia, Paycha, Frederic, Body, Jean-Jacques, Vieillard, Marie-Hélène, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service de radiologie, Thureau, Sébastien, Faivre, Jean Christophe, Assaker, Richard, Biver, Emmanuel, Confavreux, Cyrille B, Debiais, Françoise, Duterque-Coquillaud, Martine, Giammarile, Francesco, Heymann, Dominique, Lecouvet, Frédéric, Morardet, Laetitia, Paycha, Frederic, Body, Jean-Jacques, and Vieillard, Marie-Hélène

Abstract

The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.

Published
2020

27. 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis

Author

Servagi Vernat, Stéphanie, primary, Khalifa, Jonathan, additional, Sun, Xu-Shan, additional, Kammerer, Emmanuel, additional, Blais, Eivind, additional, Faivre, Jean-Christophe, additional, Sio, Terence Tai-Weng, additional, Pan, Jianji, additional, Qiu, Hao, additional, Bar-Sela, Gil, additional, Simon, Jean-Marc, additional, Salleron, Julia, additional, and Thariat, Juliette, additional

Published
2019
Full Text
View/download PDF

28. Combination of Daily Low Dose Cisplatin with Thoracic Radiation in Locally Non-Small Cell Lung Cancer for Fragile Patients: An Experimental Monocentric Serie

Author

Salleron Julia, Clément-Duchêne Christelle, Royer Philippe, Beckendorf Véronique, Peiffert Didier, Prévot Michel, Faivre Jean-Christophe, Ménard Olivier, Baumann Anne-Sophie, and Vignaud Jean-Michel

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, Performance status, business.industry, medicine.medical_treatment, Standard treatment, Retrospective cohort study, medicine.disease, Internal medicine, Medicine, Progression-free survival, Stage (cooking), business, Adverse effect, Lung cancer
Abstract

Lung cancer incidence in the elderly is rising over year. The standard treatment for locally non-small cell lung cancer (NSCLC) is based on a combination of chemotherapy and thoracic radiation. No standard is described or validated for patients older than 70 years. The objective of this retrospective study was to evaluate the toxicities and the feasibility of daily cisplatin at a dose of 6 mg/m² during thoracic irradiation (66-70 Gray) in NSCLC with poor WHO performance status, and/or comorbidities. The second objective was to obtain a first estimation of survival for patients with stage III-IV. Between 2011 and 2015, 13 patients were retrieved from the hospital database. The median age was 71.3 years, and the most frequent histologic type was squamous cell carcinoma (69%). The most frequent grade 2 adverse events were cardiac (n=3) or digestive (n=1). No pulmonary toxicity was observed. For the 10 patients with stage III-IV, the median progression free survival was 171 months. The 1-year overall survival (OS) was 90%, and the 2-years OS was 67%. The combination of daily cisplatin with thoracic radiation is effective, and well tolerated in fragile NSCLC patients. This association should be evaluated in clinical trials.

Published
2018
Full Text
View/download PDF

30. Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment

Author

Darmon, Ilan, primary, Morisse, Mony Chenda, additional, Coutte, Alexandre, additional, Blonski, Marie, additional, Rhun, Emilie Le, additional, Taillandier, Luc, additional, Roufai, Diana Bello, additional, Desenclos, Christine, additional, Trudel, Stéphanie, additional, Faivre, Jean-Christophe, additional, Blanchard, Nicolas, additional, Chauffert, Bruno, additional, and Boone, Mathieu, additional

Published
2017
Full Text
View/download PDF

31. Impact des facteurs cliniques et dosimétriques sur le contrôle local de la curiethérapie utéro-vaginale intra-cavitaire à bas débit de dose pulsée dans les cancers du col de l'utérus. Cohorte de l'Institut de Cancérologie de Lorraine

Author

Faivre, Jean-Christophe, Université de Lorraine (UL), Université de Lorraine, and Claire Charra-Brunaud

Subjects
Col de l'utérus, Curiethérapie, [SDV]Life Sciences [q-bio], Epithelioma spinocellulaire, Thèse d'exercice de médecine, Anticancéreux-Effets secondaires, Non disponible / Not available
Abstract

Introduction : l'objectif est d'évaluer l'existence d'une association entre les paramètres cliniques et thérapeutiques sur la survie sans événement local et décrire les résultats en terme de tolérance des patientes pris en charge par curiethérapie endocavitaire utéro-vaginale 3D à débit de dose pulsée dans la cohorte de l'Institut de Cancérologie de Lorraine entre 2005 et 2011 pour un cancer du col de l'utérus.Méthodes : les patientes étaient atteintes de carcinome épidermoïdes (78 %), enbon état général (OMS 1 et 2) (83 %) majoritairement de stades FIGO IB2 à II (81 %).Soixante dix neuf pourcents des patientes avaient bénéficié d'une chimiothérapieconcomitante à la radiothérapie externe. Trente sept pourcents des patientes ontbénéficié d'une chirurgie après l'irradiation. Les données ont été recueillies demanière prospective.Résultats : Le suivi médian des 162 patientes était de 27 mois. La curiethérapieintra-cavitaire utéro-vaginale à débit pulsée était réalisée avec une dose médiane aupoint A EQD2 de 65,3 Gy alpha/bêta10, une D90 du CTV HR et une D100 du CTV HR à 25,9 alpha/bêta10 et 62,7 Gy alpha/bêta10 respectivement. Les D2cc et D0,1cc étaient de 65,8 (+/- 6,4) et 77,7 (+/- 29,9) Gy alpha/bêta3 au niveau vésical et de 53,8 (+/- 5,3) et 58,0 (+/- 8,4) Gyalpha/bêta3 au niveau rectal. Les survies globale, spécifique et sans événement local à 24 mois étaient de 81,2 % (IC 95 % 73,5 ; 86,8), 83,7 % (IC 95 % 76,2 ; 89,0) et 88,1 % (IC 95 % 81,1 ; 92,6) respectivement. La survie sans événement local était corrélée au stade FIGO et à la réalisation d'une chirurgie post-irradiation ainsi qu'une dose au point A EQD2 supérieure à 68 Gy alpha/bêta3. On note 3 effets secondaires de grade 3 à 24 mois : une sténose colique, une sténose grêlique, une sténose urétérale et une fistule vésicale de grade 4.Conclusion : la curiethérapie utéro-vaginale à bas débit de dose pulsée est sûre etefficace. Les résultats de notre cohorte sont comparables aux données publiées

Published
2013

32. Évolutions dans la prise en charge des métastases ganglionnaires cervicales sans cancer primitif retrouvé : avancées diagnostiques et nouvelle classification TNM

Author

Troussier, Idriss, Klausner, Guillaume, Morinière, Sylvain, Blais, Eivind, Faivre, Jean-Christophe, Champion, Ambroise, Geoffrois, Lionnel, Pflumio, Carole, Babin, Emmanuel, Maingon, Philippe, and Thariat, Juliette

Abstract

Les métastases ganglionnaires cervicales sans cancer primitif retrouvé représentent 3 % des cancers de la tête et du cou et posent le problème des modalités diagnostiques à mettre en œuvre pour la recherche d’un éventuel cancer primitif. Cette revue fait le point sur les évolutions diagnostiques et leur impact thérapeutique potentiel.

Published
2018
Full Text
View/download PDF

33. Mobile Technology and Social Media in the Clinical Practice of Young Radiation Oncologists: Results of a Comprehensive Nationwide Cross-sectional Study.

Author

Bibault, Jean-Emmanuel, Leroy, Thomas, MDPhD, Pierre Blanchard, Biau, Julian, Cervellera, Mathilde, Diaz, Olivia, Faivre, Jean Christophe, Fumagalli, Ingrid, Lescut, Nicolas, Martin, Valentine, Pichon, Baptiste, Riou, Olivier, Thureau, Sébastien, and Giraud, Philippe

Subjects
*ONCOLOGISTS, *MEDICAL practice, *CROSS-sectional method, *SOCIAL media, *CELL phones, *INTERNET surveys, *RESIDENTS (Medicine)
Abstract

Purpose Social media and mobile technology are transforming the way in which young physicians are learning and practicing medicine. The true impact of such technologies has yet to be evaluated. Methods and Materials We performed a nationwide cross-sectional survey to better assess how young radiation oncologists used these technologies. An online survey was sent out between April 24, 2013, and June 1, 2013. All residents attending the 2013 radiation oncology French summer course were invited to complete the survey. Logistic regressions were performed to assess predictors of use of these tools in the hospital on various clinical endpoints. Results In all, 131 of 140 (93.6%) French young radiation oncologists answered the survey. Of these individuals, 93% owned a smartphone and 32.8% owned a tablet. The majority (78.6%) of the residents owning a smartphone used it to work in their department. A total of 33.5% had more than 5 medical applications installed. Only 60.3% of the residents verified the validity of the apps that they used. In all, 82.9% of the residents had a social network account. Conclusions Most of the residents in radiation oncology use their smartphone to work in their department for a wide variety of tasks. However, the residents do not consistently check the validity of the apps that they use. Residents also use social networks, with only a limited impact on their relationship with their patients. Overall, this study highlights the irruption and the risks of new technologies in the clinical practice and raises the question of a possible regulation of their use in the hospital. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

34. CyberKnife ® stereotactic radiation therapy for stage I lung cancer and pulmonary oligometastases: is fiducial implantation still relevant?-a cohort study.

Author

Oudin V, Salleron J, Marchesi V, Peiffert D, Khadige M, and Faivre JC

Abstract

Background: Few studies have investigated whether there is a difference in local control or overall survival rates following treatment with robotic stereotactic body radiation therapy (SBRT) with or without prior fiducial marker implantation. Our study aimed to investigate this in patients with primary or secondary lung tumors., Methods: A retrospective study was conducted at the Institut de Cancérologie de Lorraine of patients treated for primary lung cancer or pulmonary oligometastases with SBRT from January 2013 to July 2016. We included patients at least 18 years old who had stage I non-small cell lung cancer (NSCLC) or lung metastases and a follow-up of at least 1 month., Results: A total of 294 patients were included. Tumors included 122 lung metastases, 89 stage I NSCLC, and 83 non-histologically confirmed lung lesions. The tracking methods were Synchrony ® in 191 cases (119 gold seeds and 72 coils) and Xsight ® Spine with 4D computed tomography in 103 cases. Median follow-up was 31.6 months [interquartile range (IQR), 18.1-50.2 months]. The two- and five-year probability of local control were respectively 92.22% [95% confidence interval (CI): 0.89-0.95] and 85.35% (95% CI: 0.79-0.99). The two- and five-year probability of overall survival were respectively 87.46% and 72.77% (P=0.586). Local control rates did not significantly differ between techniques at 2 and 5 years (P=0.685) (gold seeds, coils or Xsight ® Spine) within tumors grouped by location, gross tumor volume (GTV) (respectively P=0.9, P=0.7, and P=0.4), planning target volume (PTV) (respectively P=0.4, P=0.9, and P=0.7), or PTV/GTV ratio (respectively P=0.6, P=0.6, and P=0.5). Metastasis-free survival and Overall survival rates did not significantly differ between techniques at 2 and 5 years (P=0.664 and P=0.586, respectively). There were no grade 4 or 5 toxicities and only one grade 3 pneumonitis and one grade 3 pneumothorax., Conclusions: Fiducial-less SBRT using Xsight ® Spine is a safe alternative to Synchrony ® using gold seeds or coils, with comparable local control and overall survival rates and a similar toxicity profile., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1245/coif). The authors have no conflicts of interest to declare., (2023 Journal of Thoracic Disease. All rights reserved.)

Published
2023
Full Text
View/download PDF

35. [White paper on radiation oncology in France. Twelve proposals to improve a major cancer treatment. Société française de radiothérapie oncologique].

Author

Chauvet B, Mahé MA, Maingon P, Mazeron JJ, Mornex F, Chauvet B, Mahé MA, Maingon P, Mazeron JJ, Mornex F, Azria D, Barillot I, Chauvet B, Denis F, Lartigau É, Lipinski F, Maingon P, Mornex F, Ardiet JM, Bibault JE, Caudrelier V, Diaz O, de Crevoisier R, Dubray B, Estivalet S, Faivre JC, Fenoglietto P, Fumagalli I, Ferlay J, Giraud P, Hennequin C, Henoch H, Khodri M, Llacer C, Lagrange JL, Lorchel F, Mahé MA, Meyrieux C, de Martel C, Noël G, Oozeer R, Peiffert D, Pointreau Y, Pourel N, Pradier O, Rocher F, Thureau S, Eschwège F, Martin P, and Parmentier G

Subjects
Clinical Trials as Topic, Diffusion of Innovation, Financing, Organized legislation & jurisprudence, France, Government Agencies, Health Services Accessibility legislation & jurisprudence, Health Services Accessibility trends, Humans, Informed Consent legislation & jurisprudence, Interdisciplinary Communication, Neoplasms radiotherapy, Patient Education as Topic standards, Quality Assurance, Health Care, Quality Improvement, Radiation Injuries etiology, Radiation Injuries prevention & control, Radiation Oncology education, Radiation Oncology organization & administration, Radiation Oncology trends, Radiosurgery, Radiotherapy adverse effects, Radiotherapy economics, Radiotherapy ethics, Radiotherapy instrumentation, Radiotherapy methods, Radiotherapy trends, Radiotherapy Dosage, Research, Risk Management, Societies, Medical, Societies, Scientific, Socioeconomic Factors, Staff Development, Technology, High-Cost, Translational Research, Biomedical, Workforce, Radiotherapy standards
Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results